Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

01.04.22	Form 4 78003 (RSS)
30.03.22	FDA Authorizes 2nd Booster Dose Of Pfizer, Moderna COVID-19 Vaccines (RTTNews)
30.03.22	Pfizer Announces Positive Results From Phase 3 Trial Of Etrasimod In Ulcerative Colitis (RTTNews)
30.03.22	Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential (PR Newswire)
29.03.22	FDA Gives Emergency Use Authorization To Pfizer's Second COVID-19 Booster Dose (RTTNews)
29.03.22	Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older (Businesswire)
29.03.22	Pfizer Reports Positive Top-line Results For Phase 3 Trial Of Etrasimod In Ulcerative Colitis (RTTNews)
29.03.22	Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential (Businesswire)
28.03.22	Initial statement of beneficial ownership of securities (RSS)
25.03.22	ViiV Healthcare : FDA Approves Label Update For Long-acting HIV Treatment Cabenuva (RTTNews)
24.03.22	Pfizer Says FDA Grants Breakthrough Therapy Designation For RSV Vaccine Candidate (RTTNews)
24.03.22	Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults (Businesswire)
23.03.22	Pfizer Announces Positive Topline Results For Phase 3 Study Of Etrasimod For Ulcerative Colitis (RTTNews)
23.03.22	Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients (Businesswire)
22.03.22	Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts (Businesswire)
22.03.22	Pfizer To Supply UNICEF Up To 4 Mln Oral Courses Of Paxlovid To Fight Covid-19 In 95 Countries (RTTNews)
22.03.22	Pfizer Recalls Blood Pressure Drug Accuretic, Two Generics (RTTNews)
22.03.22	Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries (Businesswire)
17.03.22	Alnylam Files Patent Infringement Suits Against Pfizer And Moderna On COVID-19 Vaccines (RTTNews)
17.03.22	Form 4 78003 (RSS)
17.03.22	Additional definitive proxy soliciting materials and Rule 14(a)(12) material (RSS)
17.03.22	Form DEF 14A 78003 (RSS)
16.03.22	Pfizer Seeks Emergency Use Authorization In U.S. For Second COVID-19 Booster Dose (RTTNews)
15.03.22	Pfizer To Continue Supplying Medicines To Russia, Halts Clinical Trials (RTTNews)
14.03.22	IDEAYA, Pfizer To Evaluate Darovasertib- Crizotinib Combination In MUM And Addl CMET-Driven Tumors (RTTNews)
14.03.22	IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors (PR Newswire)
11.03.22	Pfizer Completes Acquisition of Arena Pharmaceuticals (Businesswire)
09.03.22	Pfizer Begins Phase 2/3 Study Of COVID-19 Oral Treatment In Pediatric Participants (RTTNews)
09.03.22	Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants (Businesswire)
08.03.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
02.03.22	FDA Grants Breakthrough Therapy Designation For Pfizer's RSVpreF To Prevent RSV In Infants (RTTNews)
01.03.22	Pfizer's Covid Vaccine Not Very Effective In Children Between 5-11 Years Against Omicron Variant (RTTNews)
01.03.22	Pfizer : Phase 3 Trial Of Investigational C. Difficile Vaccine Fails To Meet Primary Goal (RTTNews)
01.03.22	Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints (Businesswire)
28.02.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
25.02.22	Biohaven, Pfizer Get Positive CHMP Opinion For Rimegepant To Treat Migraine (RTTNews)
25.02.22	Form 4 78003 (RSS)
24.02.22	Form 10-K 78003 (RSS)
22.02.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference (Businesswire)
20.02.22	FDA Considers Approving Second COVID-19 Booster Dose: Report (RTTNews)
17.02.22	Form 4 78003 (RSS)
15.02.22	Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency (Businesswire)
15.02.22	European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults (Businesswire)
14.02.22	FDA Pushes Vaccine For Children Under 5 Year Back For More Data (RTTNews)
14.02.22	Biohaven Pharma: Rimegepant Asia-Pacific Phase 3 Study Meets Co-primary Endpoints (RTTNews)
11.02.22	Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age (Businesswire)
11.02.22	Form SC 13G/A 78003 (RSS)
09.02.22	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
08.02.22	Pfizer Q4 Adj. Profit Rises; Projects 47% Operational Growth In FY22 Adj. EPS (RTTNews)
08.02.22	Pfizer Inc. Q4 Income Advances (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

21.11.24		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
21.11.24		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
21.11.24		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
21.11.24		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
21.11.24		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen
21.11.24		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
21.11.24		Novartis-Aktie fester: Novartis passt Umsatzziele nach oben an
21.11.24		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus

21.11.24

Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone

21.11.24

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

21.11.24

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

21.11.24

SDAX aktuell: SDAX zum Handelsende auf grünem Terrain

21.11.24

Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen

21.11.24

Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone